A Phase 2 Trial of Ado-Trastuzumab Emtansine for Patients With HER2 Amplified or Mutant Cancers

Trial Profile

A Phase 2 Trial of Ado-Trastuzumab Emtansine for Patients With HER2 Amplified or Mutant Cancers

Recruiting
Phase of Trial: Phase II

Latest Information Update: 18 Oct 2017

At a glance

  • Drugs Trastuzumab emtansine (Primary)
  • Indications Bladder cancer; Lung cancer; Solid tumours
  • Focus Therapeutic Use
  • Acronyms Basket
  • Most Recent Events

    • 18 Oct 2017 Results of a cohort of patients with advanced HER2 mutant or amplified lung cancers (n=33) presented at the 18th World Conference on Lung Cancer
    • 10 Jun 2017 Biomarkers information updated
    • 09 Jun 2017 Planned number of patients changed from 72 to 100.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top